Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics

Alzheimer's disease stories

Nov 15, 2026

Oyster Therapeutics raises $60M for brain-penetrating small molecule degraders

Brain-focused startup Oyster Therapeutics secured $60 million to advance its lead program targeting pathological tau in Alzheimer's disease, with Eli Lilly participating in the round.

Nov 15, 2026·3 sources
00
Oct 29, 2026

Sutter Health review board improves access to anti-amyloid Alzheimer's therapies

Sutter Health has implemented a review board system to more efficiently process referrals for anti-amyloid therapies that slow Alzheimer's disease progression, as demand for these treatments increases. The approach aims to streamline access to these disease-modifying treatments for eligible patients.

Oct 29, 2026·2 sources
00

International study identifies 127 genetic risk regions for Alzheimer's disease

A large-scale multi-ancestry genetic study led by Ole Andreassen at University of Oslo has identified new DNA risk factors for Alzheimer's disease, implicating microglial and neuronal dysregulation. The research reveals a larger common-variant contribution to the disease than previously estimated and identifies potential new drug targets.

Oct 29, 2026·3 sources
00
Oct 23, 2026

Pathos AI raises $237M led by Bristol Myers Squibb, partners on Alzheimer's drug development

AI drug development company Pathos AI announced a $237 million Series E funding round led by Bristol Myers Squibb, reaching a $3 billion valuation. The deal includes a collaboration between Pathos AI, Bristol Myers Squibb, and Tempus AI to develop artificial intelligence tools for drug development in Alzheimer's disease and other neurological disorders.

Oct 23, 2026·4 sources
00
Sep 24, 2026

Acadia's Alzheimer's psychosis drug fails mid-stage trial

Acadia Pharmaceuticals reported its experimental drug for psychosis associated with Alzheimer's disease missed the main goal of a mid-stage study testing whether it could reduce hallucinations and delusions. The company said it saw enough signal to continue with a modified Phase 3 trial.

Sep 24, 2026·3 sources
00
Aug 14, 2026

Brain autopsies reveal fewer Alzheimer's signs in woman who took menopause drug

Autopsy findings show reduced Alzheimer's pathology in a woman who used menopause medication, suggesting potential protective effects of hormone therapy on brain health.

Aug 14, 2026·2 sources
00

FDA approves Enigma Biomedical's TAUKLARIFY for Alzheimer's disease diagnosis

The FDA has approved TAUKLARIFY (florquinitau F 18 injection), a novel diagnostic imaging agent developed by Enigma Biomedical USA to identify tau neurofibrillary tangles in patients being evaluated for Alzheimer's disease, including tangles isolated to the medial temporal lobe.

Aug 14, 2026·1 source
00

Women taking estrogen-only hormone therapy showed fewer Alzheimer's signs in brain tissue

A large study of over 2,000 women found those who used estrogen-only hormone therapy later in life were less likely to develop dementia and showed fewer signs of Alzheimer's disease in their brains upon autopsy.

Aug 14, 2026·3 sources
00
Aug 3, 2026

APOE2 gene protects brain from Alzheimer's by reducing DNA damage

Research shows the longevity-linked APOE2 gene protects brain cells by reducing DNA damage and helping neurons recover from stress, potentially opening new treatment paths for Alzheimer's disease.

Aug 3, 2026·1 source
00
May 14, 2026

Biogen Advances Tau-Targeting Alzheimer's Drug to Phase 3 Despite Mixed Phase 2 Results

Biogen is moving its tau-targeting Alzheimer's drug into Phase 3 studies following a Phase 2 trial that showed mixed results.

May 14, 2026·1 source
00
Apr 23, 2026

Dopamine Loss Emerges as Key Driver of Memory Decline in Alzheimer’s

Study finds reduced dopamine signaling contributes to memory decline in Alzheimer’s, highlighting a previously underrecognized pathway and potential target for treatment.

Apr 23, 2026·3 sources
00

Top claims

  • ▪London-based Oyster Therapeutics raised $60 million in Series A-2 funding to advance its preclinical brain-penetrating small molecule degrader research in Alzheimer's disease
  • ▪Biogen reported preliminary Phase 2 data in May 2026 showing tau reduction and cognitive benefit for its antisense oligonucleotide diranersen, though the trial missed its main dose-response goal at week 76
  • ▪Oyster Therapeutics' $60 million Series A-2 round was led by 4BIO Capital, with participation from new investors Eli Lilly, Actium Group, CE Ventures, and TOHO Ventures

Subtopics

Alzheimer’s & dementia10Drug Approval and Clinical Trials4Drug Policy, Pricing & Approval4Brain health & dementia researchers3Brain longevity3Drug development3Neurodegenerative disease3Age related cognitive decline2Biomarkers & bloodwork testing2Clinical trials2Drug discovery2Menopause hormone therapy and symptom management2Neuroprotection2Reproductive Health2Women's reproductive health & fertility2Aging (Biology)1AI applications1AI companies founding rounds1AI drug discovery1AI in healthcare1AI investment1AI startups1Biotech innovation1Biotech startup1

Related timelines

Congress

110 stories

Crypto hacks

100 stories

Iran War

209 stories

Payments

118 stories

Russia-Ukraine war

136 stories